Meeting Banner
Abstract #2704

Preclinical Therapeutic Sequencing Using a Dual-Tracer Multi-Animal DCE-MRI Platform

James A. Bankson1, David L. Schwartz2, Douglas Webb1, Charles V. Kingsley1, Jorge Delacerda1, Marc S. Ramirez1, Garth Powis1

1Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States; 2Department of Radiation Medicine, North Shore-LIJ Health System, New Hyde Park, NY, United States

A dual-tracer multi-animal DCE-MRI platform has been used to compare response of a xenograft model of pancreatic cancer to combinations of radiation therapy and PX-478, a novel selective HIF-1a inhibitor currently in Phase I clinical trial. Six groups of eight animals were administered sham, single-agent, concurrent, or sequential therapies. Dual-tracer multi-animal DCE-MRI evaluation of vascular changes detected most pronounced response in group given combined therapy compared to controls as early as +3d after completion of therapy, preceding detectable differences in tumor growth by >7d. The dual-tracer multi-animal DCE-MRI platform enabled high-throughput evaluation of response to therapy.